In the light of recent findings on the role of some molecular markers in the pathogenesis and progression of this tumor [5], we have also carried out molecular analyses to verify the methylation of p16 promoter and mutational status of KRAS, PIK3CA and EGFR. The gene discussed is EGFR; the disease is neoplasm.